Interim analysis of the ongoing TIGER (CML V)-Study (NCT01657604) has shown that the rates of MR4.0 and MR4.5, which are associated with higher rates of TFR, can be improved by peg-IFN when added upfront to nilotinib [124]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.